TOKYO — Fujifilm Holdings announced on Tuesday that it has signed a contract worth more than $3 billion to manufacture biologic drugs derived from living organisms in the U.S. for a major American pharmaceutical company.
The 10-year deal with Nasdaq-listed Regeneron Pharmaceuticals comes as U.S. pharmaceutical companies are doubling down on domestic supply in response to economic security policies and tariffs applied by President Donald Trump.
